Company ProfilePremium

Noxopharm Limited

Company Profile Analysis

Ticker: NOX.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Noxopharm Limited - Company showcase

Year Founded & Workforce

2015

17 Employees

Noxopharm Limited logo

Noxopharm Limited Employee Contacts

6 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Noxopharm Limited Overview

Noxopharm began as an oncology company built around idronoxil (Veyonda®). It is now a platform company centred on Sofra™, a proprietary oligonucleotide technology in-licensed through a long-running partnership with Melbourne's Hudson Institute of Medical Research. Sofra's short synthetic nucleic acids modulate innate-immune sensors, chiefly the Toll-like receptors TLR7 and TLR8, either dampening inflammation (autoimmunity) or amplifying immune activation (immuno-oncology, mRNA-vaccine enhancement).

The lead asset, SOF-SKN™, is a topical drug for cutaneous lupus erythematosus (CLE). It completed its first-in-human HERACLES trial in January 2026 and received supportive FDA pre-IND feedback in October 2026. A 15-patient CLE study is targeted to start in Q1 CY2027.

The company runs a lean, roughly 17-person, partnership-heavy model funded by R&D tax rebates, convertible notes and chairman-linked loans. It is materially capital-constrained: at 30 June 2026 it had A$0.29m of cash, net liabilities of A$3.65m, and A$3.85m face value of notes maturing on 2 January 2027.


Company's own description

In its FY2026 preliminary report, Noxopharm describes its principal activity in three parts:

  • clinical-trial preparation for SOF-SKN™;

  • drug development aimed at new treatments for inflammation, autoimmune diseases and cancer;

  • improving mRNA vaccines.

Its standard corporate boilerplate describes it as a clinical-stage Australian biotech. The boilerplate says the company uses in-house specialists plus strategic research partnerships to build a pipeline on two platforms:

Sofra™: inflammation, autoimmunity, mRNA drug enhancement and oncology;

Chroma™: oncology.

The company describes Sofra as a new approach to drug design. It translates new knowledge of innate biology into targeted therapeutics that give precise control over disease-relevant immune signalling. It does this with synthetic oligonucleotides that mimic the body's natural regulators of immune sensors. (Sources: Appendix 4E FY2026; June 2026 Quarterly Activities Report.)

Independent characterisation

Revenue typeCurrent status (FY2026)Historical
Product sales—None ever
Services—Minor research service fees (A$36k FY2022; A$16k FY2021) and a consulting fee receivable (A$45k, related to Audio Pixels)
Licensing / milestones / royaltiesNone received to date. This is the targeted future model—
SubscriptionNot applicableNot applicable
Non-operating "income"R&D Tax Incentive refundable offset of A$1.43m (FY2026); interest incomeR&D Tax Incentive A$2.40m–A$5.99m p.a. (FY2022–FY2025)

Stage and focus. Noxopharm is a discovery-to-early-clinical stage, single-segment, Australia-based drug developer. Its strategy has narrowed sharply since 2023, and the value proposition is now almost entirely the Sofra platform:

  • SOF-SKN: topical TLR7/8 inhibition for CLE and potentially other inflammatory skin diseases.

  • SOF-VAC: an additive to reduce the inflammatory reactogenicity of mRNA vaccines and medicines, and to boost self-amplifying mRNA.

  • TLR8-amplifying oligonucleotides for immuno-oncology.

  • Partner-tested assets in inhaled and targeted delivery formats.

Chroma (oncology small molecules such as CRO-67) remains in the portfolio but receives little capital.

Business model. This is a classic "develop-to-license" biotech model. The company aims to generate data packages that are commercially attractive enough to out-license or partner, rather than to commercialise itself. Evidence for this:

  • Multiple Material Transfer Agreements (MTAs) under which third parties fund their own evaluation of Sofra assets.

  • The stated goal that an IND would make SOF-SKN more attractive to industry partners.

  • CEO performance options that historically vested on a licensing deal with a large pharmaceutical company.

Revenue model.

Value chain position. The company sits at the upstream discovery and early-clinical end of the pharmaceutical value chain. It outsources manufacturing, clinical operations and regulatory consulting:

  • Clinical trial unit: Doherty Clinical Trials, Melbourne, for HERACLES.

  • CRO: Novotech, for the FDA pre-IND process.

  • Contract manufacturing of SOF-SKN (vendor not disclosed).

Core science is co-developed with the Hudson Institute of Medical Research (Prof. Michael Gantier's laboratory).

Customer types. Prospective customers are licensees, not patients or prescribers:

  • mid-size to large biopharma;

  • mRNA-vaccine developers (CSL has presented Noxopharm data);

  • drug-delivery technology companies (Tezcat Biosciences in the US; InhaTarget Therapeutics in Belgium).

Strategy

Stated strategy themes (company language paraphrased)

  1. Prioritise the Sofra platform. Sofra is framed as a new way of designing drugs by turning innate-immune biology into precisely targeted therapeutics (FY2026 4E).

  2. De-risk and increase the commercial attractiveness of SOF-SKN through US regulatory engagement. The company states that a successful IND would raise SOF-SKN's commercial potential and appeal to partners (ASX release 6 May 2026).

  3. Use partner-funded evaluation (MTAs) to validate breadth. Counterparties bear their own costs to test Sofra assets (FY2024–FY2026 4E).

  4. Extend Sofra into immuno-oncology via TLR8 amplification, alongside autoimmunity and mRNA enhancement (June 2026 quarterly).

  5. Scientific validation through high-impact publications (Nature Immunology; Nature Reviews Rheumatology; bioRxiv manuscript with partners).

  6. Capital discipline while exploring "a range of options" for additional capital (every quarterly report since 2025).

Initiatives in the last 24 months

InitiativeDateDetailStatus
HERACLES first-in-human trial (SOF-SKN)Mid-2025 → Jan 2026Two-part, four-concentration safety study, Doherty Clinical TrialsCompleted 21 Jan 2026
Convertible note programmeJan 2025; extended Sep 2025A$2.6m secured at 12%; maturity extended to 2 Jan 2027; 520k extra options to holdersOutstanding
4F related-party financingSep 2025; Feb 2026; Jun 2026A$1.25m loan converted to notes; A$350k loan (repaid Mar 2026); A$400k facility (A$200k drawn)Ongoing
At-the-Market facility27 Feb 2026Acuity Capital, up to A$5m to 31 Jul 2031; 15m collateral sharesUndrawn at 30 Jun 2026
CEO successionApr 2026Science-led CEO (Laczka) replaces MautnerCompleted
US regulatory strategyMay–Oct 2026Novotech engaged; pre-IND request 7 Jul; feedback 8 OctPre-IND complete; IND submission undated
SOF-SKN manufacturingJun quarter 2026Controlled-environment manufacture with QC battery, for clinical supply and stability workUnder way
CLE patient extension studyAnnounced 14 Sep 2026About 15 patients, Melbourne; start targeted Q1 CY27In preparation
TLR8 immuno-oncologyMay–Aug 2026Lead oligos; humanised TLR8 modelPreclinical
Non-dilutive grantsNov 2025; Jul 2026NSW Government TechVoucher (UNSW); grant awarded to Hudson Institute for Sofra-related projectReceived / partner-held
Promotional and outreach programmeFY2026Sofra marketing to industry, clinicians and conferences (e.g. CSL presentation at Options XIII)Ongoing

ESG / sustainability commitments: none disclosed. Formal cost-reduction programme with targets: none disclosed in the last 24 months; the major restructuring was in 2023.

Management medium-term targets / guidance

MilestoneTarget timingSource
CLE extension study startQ1 CY2027 (subject to ethics, regulatory and contracts)ASX release 14 Sep 2026
Initial efficacy signalsQ2 CY2027Same
Full data readoutQ4 CY2027Same
IND submissionNot datedASX release 8 Oct 2026
Phase II CLE trial startH1 CY2028ASX release 8 Oct 2026

No financial guidance is given. The company has disclosed these clinical and regulatory timelines:

Products & Services

Noxopharm has no marketed products. The catalogue below is its development portfolio, product by product.

SOF-SKN™ (Sofra platform: autoimmune / inflammatory skin)

Description: Topical formulation of the oligonucleotide SOF-16, which inhibits TLR7/8 signalling at the skin.

Lead indication: Cutaneous lupus erythematosus (CLE). Potential follow-on indications are psoriasis and dermatomyositis.

Key data: - HERACLES first-in-human study in healthy volunteers tested four concentrations, with no relevant safety issues; completed Jan 2026.

  • Preclinical PK: skin half-life of about 3.5 days with near-zero systemic absorption at the highest HERACLES dose.

  • Ex vivo activity in blood from SLE patients and joint fluid from rheumatoid arthritis patients.

Status: - Manufacturing for future clinical supply began in the June 2026 quarter.

  • FDA pre-IND feedback was received in Oct 2026: the FDA called the Phase II design reasonable and was particularly supportive of the CMC strategy.

  • A roughly 15-patient CLE study (14 days of daily topical dosing plus 7-day follow-up; lead investigator A/Prof Amanda Saracino) is targeted to start in Q1 CY2027. Initial signals are targeted for Q2 CY2027 and full data for Q4 CY2027.

  • Phase II is targeted for H1 CY2028.

Target customer: Licensing partners in dermatology and immunology.

Pricing: Not applicable / not disclosed. The company flags a potential Orphan Drug Designation opportunity.

Sources: FY2026 4E; June 2026 quarterly; ASX releases of 6 May, 7 Jul, 14 Sep and 8 Oct 2026 (via StockWire X / InvestorPA summaries).

SOF-VAC™ (Sofra platform: mRNA vaccine and medicine enhancer)

Description: Oligonucleotide add-on designed to reduce mRNA-driven inflammation, the cause of many vaccine side effects, while preserving or improving efficacy.

Data: - Reduced mRNA-driven inflammation in an animal model (FY2024).

  • Data on improving self-amplifying mRNA vaccine activity, presented by CSL at the Options for the Control of Influenza XIII conference (Washington DC, late Aug/early Sep 2026).

Status: Preclinical, partner evaluation.

Target customer: mRNA vaccine and therapeutic developers.

Sources: FY2024 4E; June 2026 quarterly; ASX release of 1 Sep 2026 (headline only).

Sofra TLR8 immuno-oncology oligonucleotides

Description: Oligonucleotides that strongly amplify TLR8 activity versus current best-in-class clinical-stage TLR8 drugs, intended to enhance chemotherapy and radiotherapy.

Data / status: - New data released 26 May 2026 (share price rose about 37% on the day).

  • A human-relevant TLR8 animal model was built in early Jul 2026.

  • Further validating studies were announced on 4 Aug 2026 and 26 Aug 2026.

  • Preclinical.

US patent: A USPTO patent covering Sofra's potential use against various cancers was received in H1 FY2026.

Sources: June 2026 quarterly; H1 FY2026 4D; InvestSMART announcement list.

Partner-tested Sofra assets

Asset / use casePartnerDataStatus
Oligos conjugated to Tezcat delivery system (anti-inflammatory)Tezcat Biosciences (US)Successful attachment and strong anti-inflammatory activity preclinically. MoU signed in Q1 CY2026 to deepen collaborationPreclinical
Inhaled LNP-encapsulated oligos for lung inflammationInhaTarget Therapeutics (Belgium)Over 75% reduction in lung inflammation in an animal modelPreclinical
Other undisclosed MTAs"Mid-size to multibillion-dollar" companies—Evaluation

Sources: FY2026 4E; June 2026 quarterly; March 2026 quarterly.

Chroma™ platform (oncology)

CRO-67: Dual-cell therapy targeting pancreatic cancer cells and their stromal barrier cells.

  • Preclinical in vivo results: average 56.7% reduction in tumour volume and 48% slower tumour growth versus controls.

  • US FDA Orphan Drug Designation for pancreatic cancer (FY2024).

Brain cancer candidate: First-in-class preclinical programme with the University of South Australia, supported by a A$100,000 Tour de Cure grant (FY2024).

Source: FY2024 Appendix 4E.

Veyonda® (idronoxil, formerly NOX66) – legacy

Description: Idronoxil formulation developed as an adjuvant to chemotherapy and radiotherapy in late-stage cancers.

History: - DARRT-1 / DARRT-2 (prostate, with radiotherapy; FDA IND).

  • LuPIN (with LuPSMA; published in the Journal of Nuclear Medicine, Jan 2022).

  • CEP-2 (sarcoma, with doxorubicin; FDA IND; FDA ODD for soft tissue sarcoma).

  • IONIC.

  • The company-run DARRT-2 and CEP-2 trials were discontinued in 2023 because of recruitment challenges and cost.

Current: Drug supply to the investigator-initiated IONIC trial (secondary source).

Sources: FY2022 directors' report; FY2024 4E; roic.ai (secondary).

Financial Narrative

Basis. FY2022 figures come from audited statements. FY2023–FY2024 come from the FY2024 Appendix 4E.

All figures are A$ millions unless stated. Noxopharm has no operating revenue; its "income" is almost entirely the refundable R&D Tax Incentive, which the company accounts for as a government grant under AASB 120.

Income statement

Margins and growth. Gross, operating, EBITDA and net margins are not meaningful because there is no operating revenue. Revenue CAGR is not meaningful.

Other-income CAGR FY2022–FY2026 is about -28.3% p.a. (A$5.48m to A$1.45m). This mechanically tracks the decline in eligible R&D spend, because the refundable offset is 43.5% of eligible expenditure for FY2025–26 versus 48.5% in FY2023–24.

Commentary. The five-year profile has three phases.

Phase 1: high-burn clinical oncology (FY2022–FY2023): Total opex was A$15–17m p.a. while Veyonda ran three cancer trials (IONIC, DARRT-2, CEP-2) across the US, Europe and Australia. Reported losses of A$18.7m and A$15.1m were inflated by A$13.3m of cumulative fair-value write-downs on the Nyrada stake, as Nyrada's share price fell from 13.5c to 2.8c.

Phase 2: the 2023 pivot: Clinical trials closed and headcount was cut by about 40%. Opex fell 58% to A$7.0m in FY2024. The FY2024 loss of A$3.6m was flattered by a A$1.05m Nyrada mark-up.

Phase 3: platform-focused and debt-financed (FY2025–FY2026): - FY2025: R&D rose to A$4.3m as HERACLES preparation began.

  • FY2026: R&D fell to A$1.9m once HERACLES completed, and cash constraints bit.

  • Finance costs rose from A$0.03m (FY2024) to A$1.16m (FY2026), driven by 12%-coupon convertible notes plus accretion. These costs now equal about 24% of total operating expenses.

  • The capital structure therefore increasingly consumes resources that would otherwise fund R&D.

Balance sheet

Commentary.

  • Equity eroded from A$24.1m to a deficiency of A$3.65m over four years, with no equity raised since FY2021's placement and option exercises. Issued capital has been frozen at A$74.64m since FY2022.

  • The FY2026 balance sheet is essentially a R&D rebate receivable (A$1.43m) plus A$0.29m cash, set against A$4.57m of short-term borrowings.

  • No capitalised intangibles: all R&D is expensed, and the in-licensed Sofra IP is off-balance-sheet.

Cash flow

Commentary. FY2024's unusually low operating outflow (-A$0.68m) is a timing artefact: the company received the large FY2023 rebate (A$6.05m) while spending had already been cut. Excluding rebate receipts, gross cash operating costs fell from A$19.7m to A$5.2m over five years.

The rebate is effectively pre-spent. Each year's rebate has been pledged as security or advanced against:

  • the 4F loan in 2023;

  • Endpoints Capital in 2024;

  • the convertible notes in 2025–26, which are now secured on the FY2026 rebate.

Ratios

Ratios not meaningful or not applicable:

  • ROE: -57.5% (FY2022), -90.7% (FY2023), -49.1% (FY2024), -157.9% (FY2025). Not meaningful in FY2026 because average equity is negative.

  • ROIC: deeply negative and not meaningful.

  • Debt/equity: 0.00x to FY2024, 3.6x in FY2025, not meaningful in FY2026 (negative equity).

  • Net debt/EBITDA: not meaningful (negative EBITDA).

  • Interest coverage: negative, not meaningful.

  • Asset turnover: zero revenue.

  • Cash conversion cycle: no inventory or receivables cycle from customers; not applicable.

All ratios are derived from the filings above.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityCountryOwnershipFunction

Noxopharm Limited

Australia

Parent (ASX-listed)

Operating company, IP holder and licensee

Norbio Holding Pty Ltd

Australia

100%

Holding entity (function not separately disclosed)

Pharmorage Pty Limited

Australia

100%

Subsidiary (historically associated with Veyonda supply); current activity not disclosed

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Segment other income incl. R&D tax incentive (AUD Mn)

2.412.831.45

Segment loss before tax (AUD Mn)

-3.58-4.88-4.46

Other income YoY growth (%)

-60.517.5-48.8

Segment loss YoY change (%)

-76.236.5-8.8

Share of group total (%)

100100100

Platform Details

PlatformProgrammesStage (Oct 2026)Resource priority

Sofra™ – anti-inflammatory

SOF-SKN (topical, CLE)

Phase I complete; patient extension study targeted Q1 CY27; Phase II targeted H1 CY28

Highest

Sofra™ – mRNA enhancement

SOF-VAC; self-amplifying mRNA enhancer data (presented by CSL)

Preclinical

Medium (partner-led)

Sofra™ – immuno-oncology

TLR8-amplifying oligonucleotides

Preclinical (humanised TLR8 model built in 2026)

Medium

Sofra™ – partner-delivered assets

Tezcat conjugates; InhaTarget inhaled LNP

Partner preclinical

Partner-funded

Chroma™ – oncology

CRO-67 (pancreatic; FDA ODD); brain cancer programme (UniSA; Tour de Cure grant)

Preclinical

Low

Legacy – Veyonda® (idronoxil)

Supply to investigator-initiated IONIC trial

Company trials discontinued in 2023

Minimal

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Operating revenue from customers (AUD Mn)

0.040000

R&D tax incentive income (AUD Mn)

5.375.992.402.821.43

Total other income incl. interest and grants (AUD Mn)

5.486.092.412.831.45

Research and development expense (AUD Mn)

7.7810.652.944.271.94

Consulting, employee and director expense (AUD Mn)

5.404.182.973.002.10

Corporate administration expense (AUD Mn)

1.771.671.100.940.80

Depreciation and amortisation (AUD Mn)

0.260.150.000.000.00

Total operating expenses (AUD Mn)

15.2116.667.008.214.85

Operating loss before FV items and finance (AUD Mn, derived)

-9.73-10.56-4.60-5.38-3.40

EBITDA excl. FV items (AUD Mn, derived)

-9.47-10.41-4.59-5.38-3.40

Fair-value gain/(loss) on Nyrada investment (AUD Mn)

-8.86-4.451.050.470

Convertible note derivative and modification FV, net (AUD Mn)

0000.530.10

Finance costs (AUD Mn)

0.080.040.030.501.16

Pre-tax loss (AUD Mn)

-18.67-15.06-3.58-4.88-4.46

Income tax (AUD Mn)

00000

Net loss (AUD Mn)

-18.67-15.06-3.58-4.88-4.46

Basic and diluted EPS (A$ cents)

-6.41-5.15-1.22-1.67-1.50

Dividends per share (A$ cents)

00000

Weighted average shares (millions)

291.22292.24292.24292.24292.24

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents (AUD Mn)

14.013.012.321.550.29

R&D rebate receivable (AUD Mn)

5.005.982.322.811.43

Total current assets (AUD Mn)

20.839.164.774.581.83

Financial assets at FV – Nyrada (AUD Mn)

5.420.962.0100

Total assets (AUD Mn)

26.5910.136.784.581.84

Short-term debt – convertible notes incl. derivative (AUD Mn)

0002.484.37

Short-term debt – unsecured related-party loan (AUD Mn)

00000.20

Lease liabilities (AUD Mn)

0.160000

Long-term debt (AUD Mn)

00000

Total debt (AUD Mn)

0.16002.484.57

Net debt (AUD Mn; negative = net cash)

-13.85-3.01-2.320.924.28

Total liabilities (AUD Mn)

2.481.061.293.895.48

Total equity (AUD Mn)

24.129.075.500.69-3.65

Goodwill and intangibles (AUD Mn)

00000

Working capital (AUD Mn)

18.558.203.520.71-3.63

Issued capital (AUD Mn)

74.6474.6474.6474.6474.64

Accumulated losses (AUD Mn)

-58.80-72.06-70.07-74.65-78.48

NTA per share (A$ cents)

8.263.101.880.24-0.01

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Payments to suppliers and employees (AUD Mn)

-19.69-16.05-6.71-8.10-5.15

R&D tax rebate received in cash (AUD Mn)

5.865.016.052.342.81

Operating cash flow (AUD Mn)

-13.73-10.95-0.68-5.82-2.71

Capital expenditure (AUD Mn)

00000

Free cash flow (AUD Mn)

-13.73-10.95-0.68-5.82-2.71

Proceeds from investments – Nyrada sale (AUD Mn)

0002.480

Equity issued incl. option exercise (AUD Mn)

1.200000

Net convertible notes and borrowings (AUD Mn)

0002.601.45

Dividends paid (AUD Mn)

00000

Share buybacks (AUD Mn)

00000

Net change in cash (AUD Mn)

-12.76-11.00-0.68-0.75-1.26

Margin Analysis (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Return on assets (%, net loss / avg total assets)

-50.1-82.0-42.3-85.9-138.9

Current ratio (x)

9.139.523.831.180.34

R&D expense as % of total opex (%)

51.163.941.952.040.1

Finance costs as % of total opex (%)

0.50.20.46.123.9

Gross operating cash burn excl. rebates (AUD Mn)

19.6916.056.718.105.15

Results by Region and Region Margins & Growth (%)

RegionFY2024FY2025FY2026

Australia – total other income (AUD Mn)

2.412.831.45

Americas – operating revenue (AUD Mn)

000

EMEA – operating revenue (AUD Mn)

000

APAC ex-Australia – operating revenue (AUD Mn)

000

Australia income YoY growth (%)

-60.517.5-48.8

Per-Share Data

MetricFY2017FY2018FY2019FY2020FY2021FY2022FY2023

Share price at 30 June (A$ cents)

36.561.047.516.564.519.54.3

Per-Share Data (FY2018–FY2022)

MetricFY2018FY2019FY2020FY2021FY2022

Share price FY high (A$ cents)

158.072.045.9295.069.5

Share price FY low (A$ cents)

29.035.58.3918.517.5

Change by Horizon

HorizonChangeBasis

1-year (to 28 Sep 2026)

About -39%

Investing.com

3-year

About +40%

30 Jun 2023 price of A$0.043 to about A$0.060

5-year

About -91%

30 Jun 2021 price of A$0.645 to about A$0.060 (approximate, period-end based)

Capital Markets

MetricValue (Oct 2026)Comment

Market capitalisation

About A$18.4–19.1m

About 307m shares including 15m ATM collateral shares

Enterprise value

About A$22.8m

Market cap about A$18.9m + convertible notes (A$3.85m face) and 4F loan (A$0.2m) − cash (A$0.29m at 30 Jun 2026)

EV / annual R&D spend

About 11.7x

Analyst metric (A$22.8m / A$1.94m FY2026 R&D)

Capital Instruments

InstrumentFace / drawnRateMaturitySecurity

Convertible notes (original holders)

A$2.60m

12% (interest capitalised from 2 Jan 2026)

2 Jan 2027

Secured on FY2025/26 R&D rebate

Convertible notes (4F Investments)

A$1.25m

12%

2 Jan 2027

Unsecured

4F loan facility

A$0.20m drawn of A$0.40m

12% capitalised

On next capital raising (no fixed date)

Unsecured

Acuity ATM

A$5.0m limit, undrawn

—

31 Jul 2031

15m collateral shares

Analyst Conclusions

Management guidance

No financial guidance is given. Operational guidance:

  • CLE extension study to start in Q1 CY2027, with initial efficacy signals in Q2 CY2027 and full data in Q4 CY2027.

  • Phase II targeted for H1 CY2028.

  • IND submission in preparation, not dated.

Management has said in each quarter that it is reviewing the timing, method and amount of additional funding, and has noted it is weighing near-term catalysts in its funding timing (June 2026 Appendix 4C).

Consensus growth expectations: none (no coverage).

Bull case

  1. Clinical proof-of-concept could re-rate the platform. If the 15-patient CLE study shows clear skin-lesion improvement in 2027 on a safe, topical, non-systemic profile, SOF-SKN becomes a partnerable asset in an indication with no specifically approved therapy. That would happen with the FDA already aligned on Phase II design and CMC, from an EV of only about A$23m.

  2. Platform optionality is underpriced. At the current EV, the market ascribes little value to:

    • SOF-VAC / sa-mRNA (CSL-presented data);

    • TLR8 immuno-oncology;

    • partner-delivered assets (Tezcat, InhaTarget);

    • CRO-67 (FDA ODD). A single licence or option deal could exceed the current market capitalisation.

  3. Lean model and R&D incentive reduce cost per milestone. Opex below A$5m p.a. with a 43.5% refundable offset means a modest raise (for example A$5–8m) could fund the CLE study and IND-enabling work.

Bear case

  1. The balance sheet dictates outcomes. Net liabilities are A$3.65m, cash is A$0.29m and A$3.85m of notes plus interest fall due on 2 Jan 2027. The share price (about A$0.06) sits below the A$0.07 conversion floor. A deeply dilutive recapitalisation, a note restructuring on lender-favourable terms, or both, appears likely before the CLE study can start.

  2. Competition and mechanism risk. Merck KGaA's enpatoran shares the TLR7/8 mechanism with far greater resources, and Biogen and AstraZeneca have late-stage assets in CLE. Oligonucleotide TLR antagonists have failed before (Idera). Healthy-volunteer safety says little about efficacy.

  3. Governance and execution risk. The chair is also the principal lender, the board is a three-person minimum, CEO and Company Secretary changed in 2026, and the company has a history of abandoning its prior lead programme (Veyonda). Repeated near-zero cash positions reduce negotiating leverage with partners.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Oct–Nov 2026FY2026 audited accounts and auditor's going-concern language; FY2026 Annual Report; 2026 AGM resolutions (placement capacity, director elections, note terms)
Q4 CY2026Capital raising (placement / entitlement / ATM drawdowns) and terms; status of possible trading halt
By 2 Jan 2027Repayment, extension or conversion of A$3.85m notes; use of FY2026 R&D rebate (about A$1.43m)
Q1 CY2027Ethics approval and first patient dosed in CLE extension study
H1 CY2027Initial efficacy signals (Q2 CY27); IND submission timing; ODD application for SOF-SKN
RollingPartner news (Tezcat MoU conversion, InhaTarget, CSL / sa-mRNA, undisclosed MTAs); Hudson licence renewal; new patents
QuarterlyAppendix 4C cash, burn and related-party loans

Analyst verdict

Noxopharm in October 2026 is a company whose science has moved forward faster than its balance sheet.

On the scientific side the progress is real. Over the past eighteen months the company has:

  • taken a novel oligonucleotide platform from preclinical concept through a clean first-in-human study (HERACLES);

  • secured publication in Nature Immunology;

  • attracted third-party validation from partners in the US, Belgium and, via conference presentation, CSL;

  • obtained FDA pre-IND feedback endorsing its Phase II design and manufacturing strategy for a topical CLE therapy.

For a company spending under A$5 million a year, that is efficient progress.

The financing structure undermines it. Equity has turned negative, cash is below one quarter's burn, and A$3.85 million of 12% notes fall due on 2 January 2027. Those notes are only partly secured by an R&D rebate already earmarked for repayment, and their conversion floor sits above the current share price. The company has funded itself since 2023 through rebate advances and, increasingly, loans from entities linked to its chairman. That has kept the lights on, but it has concentrated influence in a creditor-director, and every new milestone is negotiated from weakness.

The investment question is therefore not whether Sofra works scientifically; the early evidence is encouraging. It is whether existing shareholders will retain a meaningful share of the value if it does. A recapitalisation at or below current prices appears close to unavoidable before the CLE study can start in Q1 CY2027. Its size and terms will largely determine per-share outcomes.

Verdict: a high-risk, binary-outcome speculative situation. A credible funding package or a partnering deal, rather than further preclinical news, is the gating catalyst for any re-rating.


APPENDIX: SOURCES

Primary filings (ASX):

  • Appendix 4E FY2026 (28 Aug 2026): investorpa.com/announcement-pdf/20260828/335270.pdf

  • Appendix 4D and Interim Report H1 FY2026 (27 Feb 2026): announcements.asx.com.au/asxpdf/20260227/pdf/06wwdbdy4r929n.pdf

  • Appendix 4E FY2025 (29 Aug 2025): announcements.asx.com.au/asxpdf/20250829/pdf/06njv8b5cvnnhp.pdf

  • Appendix 4E FY2024 (29 Aug 2024): announcements.asx.com.au/asxpdf/20240829/pdf/06769r16ht7x01.pdf

  • Appendix 4E and Audited FS FY2022 (25 Aug 2022): asx.com.au/asxpdf/20220825/pdf/45d981l6f1x810.pdf

  • Appendix 4E FY2021 and FY2020: asx.com.au/asxpdf/20210826/pdf/44zsqry2f94fpt.pdf; asx.com.au/asxpdf/20200831/pdf/44m448dyjbttlj.pdf

  • Appendix 4D H1 FY2025 (25 Feb 2025): announcements.asx.com.au/asxpdf/20250225/pdf/06fxhk1crdbnbm.pdf

  • June 2026 Quarterly Activities Report and Appendix 4C (22 Jul 2026): bulletin.webull.com/qbd/announcement/20260722/499501373/2be3768cc33caead016586a3311a0128.pdf

  • Resignation of CEO (14 Apr 2026): announcements.asx.com.au/asxpdf/20260414/pdf/06yg8z0454qkqh.pdf

  • Appointment of Dr Olivier Laczka (15 Apr 2026): announcements.asx.com.au/asxpdf/20260415/pdf/06yhmbt1t28dpx.pdf

  • Pre-IND meeting request (7 Jul 2026): announcements.asx.com.au/asxpdf/20260707/pdf/071g5p923btz3b.pdf

Secondary / aggregator sources (used where flagged):

  • InvestorPA summaries (Mar 2026 quarterly; Jun 2026 quarterly; 6 May 2026 release)

  • InvestSMART (announcement lists, directors, director trades, market cap)

  • StockWire X (8 Oct 2026 FDA feedback; 14 Sep 2026 CLE study)

  • Investing.com (price, 52-week range, market cap)

  • Morningstar (employees, profile)

  • Market Index (historical FY-end prices, announcement metadata)

  • TipRanks, StockAnalysis (aggregated financials; discrepancies noted)

  • roic.ai (2023 restructuring summary)

  • MarketScreener (Laczka and Mautner profiles)

  • Finance News Network; Grafa; Biotech Dispatch; SmallCaps; Kalkine; BioWorld; IBISWorld; Pearler; Simply Wall St; financialfilings.com

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackgroundIndependence (assessment)

Frederick (Fred) Bart

Non-Executive Chairman

8 May 2020 per InvestSMART; already a director in FY2021 per filings

MD of Textile Industries Australia (1985); founder of the Bart Group (hotels, retail, property, technology); former Chairman of Electro Optic Systems (resigned Jul 2021); Chairman of Audio Pixels Holdings; director of Weebit Nano; director and majority shareholder of Immunovative Therapies (Israel)

Not independent in substance. His vehicle 4F Investments is the company's principal lender and noteholder: A$1.25m of unsecured notes plus a A$0.4m loan facility

Peter Marks

Non-Executive Director & Deputy Chairman

15 Mar 2016

More than 35 years in corporate advisory, investment banking and capital markets (Australia, US, Israel). BEc, LLB, Grad Dip Commercial Law (Monash); MBA (Edinburgh). Directorships include Alterity Therapeutics; formerly Nyrada and Elsight

Nominally independent. Tenure exceeds 10 years, which ASX guidance treats as potentially affecting independence

Boris Patkin

Non-Executive Director

25 Mar 2020

Investment adviser and business consultant (Morgans Financial authorised representative); BSc (Industrial Chemistry); Chairman of Ausmon Resources

Nominally independent

Executive Leadership Team

NameTitleTenureBackground / educationRemuneration (latest disclosed)

Dr Olivier Laczka

Chief Executive Officer

Since 15 Apr 2026. Previously CSO – Inflammation; earlier Director of Drug Discovery & Research

Driving force behind the Sofra platform. Engineering degree (Ecole Supérieure d'Ingénieur de Luminy); PhD (Autonomous University of Barcelona, 2009); IUT Nantes (secondary: MarketScreener)

Fixed A$290,000 p.a. plus 12% superannuation. 2m performance options at a strike 25% above the next placement price, expiring 4 years after grant. 3-month notice (ASX release 15 Apr 2026)

Shawn van Boheemen

Company Secretary (finance function)

Appointed about 30 Apr 2026 (replacing David Franks of Automic)

Previously provided consulting services (finance) through the company

—

Julian Elliott

Investor, corporate and media relations

Ongoing

——

Dr Gisela Mautner (former)

CEO & MD

Feb 2022 – 14/15 Apr 2026; joined 2019 as CMO

MD (TU Munich), PhD (LMU Munich), MPH (Harvard), MBA (Kellogg). Formerly Amgen, Bayer, Siemens Medical, Merck/MSD

FY2022 contract A$410,000 + 10% super. FY2022 KMP total A$833,980 (of which A$621,074 share-based)

Dr Graham Kelly (former)

Founder; Executive Chair/CEO to Feb 2022; then NED

—

Founder of Novogen and Nyrada

FY2022 total A$408,238

“—” = not publicly disclosed.

Directors' Remuneration

KMPCash salary/feesSuperShare-basedTotal

Fred Bart (Chair)

41,0953,905045,000

Graham Kelly

384,49623,7420408,238

Peter Marks

60,0000060,000

Boris Patkin

45,000058,669103,669

Gisela Mautner (from 1 Feb 2022)

200,54320,054621,074

833,980 (incl. leave items)

Total KMP

———

1,450,887

Major Shareholders

Holder (Aug 2022)Shares%

Milligene Pty Ltd (GE & PR Kelly Family A/c), two lines

35,649,10612.20

Mrs Eleanore Goodridge

14,121,0854.83

RGT Capital Fund No 5 (NOXO) Pty Ltd

6,500,3332.22

Kale Capital Corporation Ltd

6,255,2902.14

Link Traders (Aust) Pty Ltd, two lines

10,471,5223.59

HSBC Custody Nominees (Australia) Ltd

4,592,1031.57

Grandor Pty Ltd (Mark Scott Family P/F)

3,395,8501.16

RHLC Pty Ltd

3,300,0001.13

Jamber Investments Pty Ltd

3,252,7621.11

Bart Superannuation Pty Ltd (4F Investments Superfund)

3,080,1891.05

Competitive Landscape

Competitors by Segment

AreaCompetitorAsset / approachRelative positioning vs Noxopharm

CLE / lupus – TLR7/8 inhibition

Merck KGaA (Germany)

Enpatoran, oral TLR7/8 inhibitor in CLE/SLE trials

Same mechanism, systemic oral delivery, far better funded. Noxopharm differentiates on topical, skin-retained delivery

CLE / SLE – pDC targeting

Biogen (US)

Litifilimab (anti-BDCA2 antibody), late-stage in CLE and SLE

Most advanced CLE-specific competitor; injectable biologic

CLE / SLE – type I interferon

AstraZeneca (UK)

Anifrolumab (Saphnelo), approved in SLE; being studied in CLE

Approved product in adjacent indication; IV/SC biologic

SLE – B-cell / BAFF

GSK (UK)

Belimumab (Benlysta), approved SLE and lupus nephritis

Standard of care in systemic disease; not skin-targeted

SLE / CLE – TYK2

Bristol Myers Squibb (US)

Deucravacitinib in lupus programmes

Oral small molecule; broad immunology franchise

Lupus / autoimmune – other

Johnson & Johnson, Novartis, Roche, others

Multiple biologic and small-molecule lupus programmes

Crowded systemic lupus field

Oligonucleotide TLR antagonists (historical)

Idera Pharmaceuticals (US)

IMO-8400 (TLR7/8/9 antagonist), discontinued in dermatomyositis

Precedent for oligonucleotide TLR modulation and its clinical risk

TLR8 agonists – immuno-oncology / antiviral

Gilead (selgantolimod); motolimod (formerly VentiRx)

TLR8 agonists

Noxopharm claims stronger TLR8 amplification than best-in-class clinical drugs (company assertion, preclinical)

mRNA reactogenicity / potency

Moderna, BioNTech, CSL/Arcturus (sa-mRNA), CureVac

In-house formulation, nucleoside modification, LNP optimisation

Potential partners as much as competitors; Noxopharm offers an additive

ASX micro-cap immunology / oncology peers

Nyrada (NYR), Alterity (ATH), Kazia (KZA, Novogen successor), Immuron (IMC)

Various

Compete for the same small-cap biotech capital

Peer Comparison FY2026

CompanyLatest FY revenueR&D intensitySource / status

Noxopharm (FY2026)

A$0 operating revenue (A$1.45m other income)

n/m (R&D 40% of opex)

FY2026 4E

AstraZeneca (FY2024)

about US$54.1bn

about 25% (approx.; verify against 2024 Annual Report)

AstraZeneca FY2024 annual report (figures from analyst recollection; verify)

Biogen (FY2024)

about US$9.7bn

about 21% (approx.; verify)

Biogen 2024 Form 10-K (verify)

Merck KGaA (FY2024)

about €21.2bn net sales

—

Merck KGaA 2024 annual report (verify)

Recent Developments

Investors should verify the current ASX trading status directly.

Company Snapshot

17

Employees

2015

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Phase I safety established. HERACLES completed in Jan 2026 across four concentrations with no relevant safety issues (FY2026 4E).
  • Regulatory alignment. The FDA pre-IND response (8 Oct 2026) was supportive, called the Phase II design reasonable and was particularly supportive of CMC.
  • Scientific validation. The foundational paper appeared in Nature Immunology (2026), followed by inclusion in a Nature Reviews Rheumatology review (June 2026 quarterly).
  • Differentiated pharmacology. About 3.5-day skin half-life with near-zero systemic absorption (preclinical PK, Apr 2026).
  • Partner pull. Tezcat (MoU 2026), InhaTarget (more than 75% reduction in lung inflammation in an animal model) and CSL's presentation of Sofra sa-mRNA data (June 2026 quarterly).
  • Very lean cost base. Total opex was A$4.85m in FY2026, down from A$16.66m in FY2023, and the company has a track record of collecting the R&D rebate every year (FY2022–FY2026 filings).
  • IP progress. First US Sofra patent granted 22 Oct 2025, plus an oncology-use patent (H1 FY2026 4D).

Weaknesses

  • Liquidity. Cash was A$293k at 30 Jun 2026; net cash used in operations was A$859k in the June quarter (June 2026 Appendix 4C).
  • Negative equity. Net liabilities of A$3.65m and working capital of -A$3.63m at 30 Jun 2026 (FY2026 4E).
  • Expensive debt. Notes carry 12% interest; finance costs reached A$1.16m (24% of opex) in FY2026 (FY2026 4E Note 3).
  • Related-party financing concentration. Three 4F facilities in FY2026 (A$1.25m, A$350k, A$400k) create governance and independence concerns (FY2026 4E Note 7).
  • Board. Three NEDs, no women, chair also principal lender, deputy chair tenure more than 10 years (H1 FY2026 4D; InvestSMART).
  • Incentive misalignment and failure. All 2.2m loan-funded performance shares were forfeited in Dec 2025 (H1 FY2026 4D).
  • Legacy write-off. About A$78.5m of accumulated losses, including a discontinued Veyonda franchise that once carried FDA ODD and INDs (FY2026 4E; FY2022 report).

Opportunities

  • CLE patient data in 2027. Initial signals in Q2 CY27 and full data in Q4 CY27 (ASX 14 Sep 2026) could catalyse partnering.
  • Orphan Drug Designation for SOF-SKN. The company itself identifies this opportunity (ASX 8 Oct 2026).
  • IND filing. Management says it would raise SOF-SKN's commercial potential (ASX 6 May 2026).
  • sa-mRNA enhancement via large-pharma relationships. CSL presented the data at Options XIII (Sep 2026).
  • Immuno-oncology expansion. TLR8 amplification claimed superior to best-in-class clinical drugs (June 2026 quarterly), in a market the company cites as US$35bn growing to US$185bn.
  • Out-licensing of non-core assets. CRO-67 (FDA ODD, pancreatic) and inhaled/conjugate formats could provide non-dilutive cash (FY2024 4E; June 2026 quarterly).

Threats

  • Note maturity. A$3.85m face value due 2 Jan 2027 plus capitalised interest. The FY2026 rebate securing it (A$1.43m receivable) covers less than 40% (FY2026 4E Note 6).
  • Dilution risk. The ATM (15m collateral shares), a conversion price that resets to any lower capital-raise price, and necessary equity raises at about A$0.06 or lower could heavily dilute holders (4D H1 FY2026).
  • Competitive pre-emption. Large-pharma TLR7/8, BDCA2 and IFN agents (enpatoran, litifilimab, anifrolumab) may establish CLE standards of care before 2028.
  • R&D incentive regime risk. AusIndustry can review four years of claims, with potential clawback (critical estimates note, FY2024 4E).
  • Licence economics. Phase III and marketing-authorisation milestones plus royalties to the licensor reduce partner economics (FY2026 4E Note 8).
  • Going-concern risk. The reliance on new funding is explicit in every quarterly report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Apr 2025March 2025 quarterly reportRoutine; runway focus
2 May 2025Clinical trial submission for SOF-SKN (HERACLES)Start of the regulatory step toward first-in-human dosing
May 2025Second MTA with InhaTargetExpanded partner testing (lung inflammation)
Mid-2025HREC ethics approval for HERACLES; Doherty Clinical Trials selectedEnabled recruitment
28 Jul 2025HERACLES Update 1 (dosing under way)First clinical dosing of a Sofra asset
30 Jul 2025June 2025 quarterly reportRoutine
11 & 25 Aug 2025HERACLES Updates 2 and 3Safety progression through cohorts
28 Aug 2025Sofra technology platform presentationInvestor positioning
29 Aug 2025FY2025 Appendix 4E: net loss A$4.88m (+36.5%)Loss widened on higher R&D and finance costs
8 Sep 2025HERACLES Update 4No safety issues reported
23 Sep 2025Convertible notes (A$2.6m) extended to 2 Jan 2027; 520k options to noteholdersAvoided Jan 2026 repayment; security rolled to FY2026 rebate
25 Sep 2025A$1.25m unsecured loan from 4F Investments (Chairman-related), 12%Liquidity bridge; related-party dependence
29 Sep 2025Audited FY2025 financial statements—
13 Oct 2025FY2025 Annual Report; Corporate Governance Statement; AGM notice—
22 Oct 2025First US patent for Sofra platformIP validation in the key market
30 Oct 2025September 2025 quarterly: cash A$935k; operating outflow A$1.9mVery short runway
5 Nov 2025HERACLES Part 2 beginsTrial progression
11 Nov 2025NSW Government grant (TechVoucher) for UNSW collaborationSmall non-dilutive funding
17 Nov 2025First dose in HERACLES Part 2—
18 Nov 2025AGM; all resolutions passed, incl. remuneration report and conversion of 4F loan into notesGovernance approvals
3 Dec 2025HERACLES Update 5—
12 Dec 20251.25m convertible notes (A$1.25m) issued to 4F; Chair's interest noticeRelated-party financing formalised
2 Jan 2026Cessation and unquoted securities notices; noteholders paid cash interest (A$368k aggregate)Interest drain
21 Jan 2026HERACLES successfully completed (four concentrations, no relevant issues)Key de-risking milestone
30 Jan 2026December 2025 quarterly—
Q1 2026Nature Immunology publication on Sofra scienceScientific credibility
27 Feb 2026A$2.81m FY2025 R&D rebate received; A$5m Acuity ATM; H1 FY2026 results (loss A$1.84m)Liquidity relief; standby equity
Feb–Mar 2026A$350k 4F loan drawn and repaid from rebateBridge financing
14 Apr 2026CEO & MD Gisela Mautner resignsLeadership change
15 Apr 2026Dr Olivier Laczka appointed CEO (share price +41% from A$0.058 over following weeks)Science-led leadership
Apr 2026SOF-SKN preclinical PK: about 3.5-day skin half-life, minimal systemic absorptionSupports dosing regimen
24 Apr 2026March 2026 quarterly: cash A$950k; Tezcat MoUPartnering progress
27 Apr 2026New collaboration expanding Sofra platformBD funnel
30 Apr 2026New Company Secretary appointed (replacing David Franks)Administrative
6 May 2026Novotech engaged ahead of FDA pre-INDUS regulatory path
8 May 2026Possible capital action
26 May 2026New data on TLR8 cancer-fighting potential (stock +36.7% from A$0.060)Immuno-oncology optionality
25 May / 1 Jun 2026Change of director's interest (Patkin)Administrative
Jun quarter 2026SOF-16 activity in SLE and RA patient samples; SOF-SKN dosing-regimen dataTranslational support
Jun quarter 2026SOF-SKN manufacturing begins (price-sensitive release, InvestSMART dated 9 Jun 2026)Clinical supply readiness
22 Jun 2026A$200k unsecured loan from 4F (facility A$400k), repayable on next capital raiseContinued related-party dependence
Early Jul 2026Humanised TLR8 animal model for immuno-oncologyPreclinical tool
7 Jul 2026Formal pre-IND meeting request to FDA; Hudson Institute receives government grant for Sofra-related projectRegulatory milestone
22 Jul 2026June 2026 quarterly: cash A$293k; operating outflow A$859k; InhaTarget data (more than 75% inflammation reduction)Critical liquidity
4 Aug 2026New study further validates cancer pipelinePreclinical
26 Aug 2026New preclinical data supporting immuno-oncology approachPreclinical
28 Aug 2026FY2026 Appendix 4E: loss A$4.46m (-8.8%); net liabilities A$3.65mBalance-sheet deficiency
1 Sep 2026Novel oligonucleotide data presented at Options XIII conference (CSL)Third-party validation
14 Sep 2026CLE patient extension study announced (about 15 patients; start Q1 CY27)Next clinical step
Late Sep 2026Share price about A$0.060; market cap about A$18.4m; 1-year change about -39%Market scepticism on financing
8 Oct 2026FDA pre-IND feedback supportive; Phase II targeted H1 CY28Regulatory de-risking

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Operating revenue from customers fell from AUD 0 Mn in FY2022 to AUD 0 Mn in FY2026.
Noxopharm Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Operating revenue from customers00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.